FABP4 and fatty liver disease: Treatment with recombinant bone morphogenetic protein 9 (BMP9) alleviated hepatic steatosis and decreased liver macrophage infiltration in mice fed with a high fat diet, partially via decreasing the FABP4 promoter chromatin accessibility and the subsequent reduction in the FABP4 expression [141].